Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients

Christopher M. Rubino, PharmD,* Mark Polak, MD,† Sebastian Schröpf, MD,‡ Hans Georg Münch, MD,§ Anne Smits, MD, PhD,§ Veerle Cossey, MD, PhD,§ Tomasz Tomasik, MD, PhD,¶ Przemko Kwinta, MD, PhD,‖ Rima Snariene, MD, ** Arunas Liubysys, MD, ** Dace Gardovska, MD, † † Chi Dang Hornik, MD, † † Miroslava Bosheva, MD, PhD, §§ Christine Ruehle, PhD, ‡ ‡ Karine Litherland, PhD, §§ and Kamal Hamed, MD, MPH † †

Background: Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced-generation, broad-spectrum, intravenous cephalosporin, which is currently approved for the treatment of adults with hospital-acquired or community-acquired pneumonia.

Methods: Noncompartmental pharmacokinetics and safety were analyzed from 2 recently completed pediatric studies, a single-dose, phase 1 study in neonates and infants up to 3 months of age (7.5 mg/kg) and a phase 3 study in patients 3 months to 17 years of age with pneumonia (10–20 mg/kg with a maximum of 500 mg per dose every 8 hours for up to 14 days).

Results: Total ceftobiprole plasma concentrations peaked at the end of infusion. Half life (median ranging from 1.9 to 2.9 hours) and overall exposure (median AUC ranging from 66.6 to 173 μg·h/mL) were similar to those in adults (mean ± SD, 3.3 ± 0.3 hours and 102 ± 11.9 μg·h/mL, respectively). Calculated free-ceftobiprole concentrations in the single-dose study remained above a minimum inhibitory concentration (MIC) of 4 mg/L (ft > MIC of 4 mg/L) for a mean of 5.29 hours after dosing. In the pneumonia study, mean ft > MIC of 4 mg/L was ≥5.28 hours in all dose groups. Ceftobiprole was well tolerated in both studies.

Conclusions: Pharmacokinetic parameters of ceftobiprole characterized in the pediatric population were within the range of those observed in adults. In the pneumonia study, the lowest percentage of the dosing interval with ft > MIC of 4 mg/L was 50.8%, which suggests that pharmacokinetic-pharmacodynamic target attainment can be sufficient in pediatric patients. Ceftobiprole was well tolerated.

Key Words: ceftobiprole, cephalosporin, pharmacokinetics, noncompartmental analysis, pediatric patients

Pediatr Infect Dis J 2021;40:997–1003

Ceftobiprole is the active moiety of the prodrug ceftobiprole medocaril and is an advanced-generation intravenous (IV) cephalosporin with broad activity against Gram-positive and Gram-negative organisms including methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. aureus, penicillin-resistant Streptococcus pneumoniae, Enterococcus faecalis, and Pseudomonas aeruginosa.1–3 It is approved for the treatment of hospital-acquired pneumonia, excluding ventilator-associated pneumonia, and community-acquired pneumonia in adults in many European and non-European countries.4 Ceftobiprole is currently under investigation to support a New Drug Application in adults in the United States for acute bacterial skin and skin structure infections and S. aureus bacteremia, including infective endocarditis.5,6 The spectrum of activity and well-established safety profile of ceftobiprole make it an attractive candidate for the treatment of infections in the pediatric population.6

The pharmacokinetics (PK) of ceftobiprole have been established in adults in both healthy volunteers and infected patients.8–11 In adults, ceftobiprole exhibits linear PK across a broad range of IV doses and exhibits limited accumulation with repeated dosing because of its short half life (T1/2) of approximately 3 hours.4,8,9 Cefotibiprole undergoes minimal hepatic metabolism and is rapidly eliminated, primarily unchanged, by glomerular filtration, with 80–90% of the dose recovered in urine. The primary metabolite is the β-lactam ring-opened hydrolysis product (opening metabolite), which accounts for 5% of the dose recovered in urine12; systemic exposure of the open-ring metabolite accounts for 95% of the dose recovered in urine.13
A thorough evaluation of the PK of ceftobiprole in pediatric patients is critical to substantiating appropriate dosing in this population. To date, minimal data have been published regarding the PK of ceftobiprole in pediatric patients. Thus, a primary aim of these analyses was to describe the PK of ceftobiprole using data collected from 2 recently completed pediatric studies, BPR-PIP-001 and BPR-PIP-002. In addition, the safety and tolerability of ceftobiprole in patients enrolled in Study BPR-PIP-001 will be described along with a brief overview of the safety of ceftobiprole in Study BPR-PIP-002, which has been described in full previously.

**MATERIALS AND METHODS**

**Study BPR-PIP-001** Study BPR-PIP-001 was a multicenter, open-label, single-dose, phase 1 study conducted to evaluate the PK and safety of ceftobiprole in neonates and infants up to 3 months of age undergoing treatment with systemic antibiotics (ClinicalTrials.gov identifier: NCT02527681; EudraCT number: 2013-004614-18). A total of 45 subjects, stratified for gestational age and GA, were to be enrolled in 3 sequential cohorts: (1) full-term infants (GA ≥37 weeks), (2) infants with GA 33–36 weeks, and (3) infants with GA of 28–32 weeks. Because of slow enrollment, the study was completed after enrollment of the full-term cohort and with no preterm subjects enrolled. All subjects received a single dose of IV ceftobiprole 7.5 mg/kg administered over 4 hours, which was selected as a conservative dose with a high margin of safety given that (1) the primary objective of this study was to evaluate the PK of ceftobiprole in this age group and (2) subjects were on standard-of-care antibiotics during the study; therefore, there was no expectation that ceftobiprole exposure would be effective clinically.

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) occurring between administration of the study medication and the follow-up visit on day 7 ± 3 days. Blood and urine samples were analyzed for safety laboratory parameters at screening and the follow-up visit on day 7 ± 3 days. Vital signs were measured within 15 minutes predose and at 1, 2.25, and 6 hours after the start of infusion. Physical examination was performed at screening, day 1, and day 7 ± 3 days.

Blood samples for PK analysis were obtained predose and at 2, 4, 6, 8, and 12 hours after the start of dosing. Urine samples were collected before, during, and after dosing. Plasma and urine were analyzed for total concentrations of ceftobiprole, ceftobiprole medocaril, and the open-ring metabolite using the liquid chromatography-tandem mass spectrometry assay described above.

**Study BPR-PIP-002** Study BPR-PIP-002 was a multicenter, randomized, investigator-blinded, active-controlled, phase 3 study to evaluate the safety, tolerability, PK, and efficacy of ceftobiprole versus IV standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients from 3 months to 17 years of age, with a primary objective of this study was to evaluate the PK of ceftobiprole in this age group and (2) subjects were on standard-of-care antibiotics during the study; therefore, there was no expectation that ceftobiprole exposure would be effective clinically.

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) occurring between administration of the study medication and the follow-up visit on day 7 ± 3 days. Blood and urine samples were analyzed for safety laboratory parameters at screening and the follow-up visit on day 7 ± 3 days. Vital signs were measured within 15 minutes predose and at 1, 2.25, and 6 hours after the start of infusion. Physical examination was performed at screening, day 1, and day 7 ± 3 days.

Blood samples for PK analysis were obtained predose and at 2, 4, 6, 8, and 12 hours after the start of dosing. Urine samples were collected before, during, and after dosing. Plasma and urine were analyzed for total concentrations of ceftobiprole, ceftobiprole medocaril, and the open-ring metabolite using the liquid chromatography-tandem mass spectrometry assay described above.

**Noncompartmental PK Analysis** All dataset creation, graphical presentations of data, and calculation of PK parameters (detailed below) were conducted using R, version 3.6.1. For the purposes of plotting the data and calculating PK parameters, plasma and urine concentration values that were below the lower limit of quantification were set to missing.

PK parameters were calculated using the actual times of sample collection. Maximum observed plasma concentration (Cmax) and time of maximum observed plasma concentration (Tmax) were derived directly from the serum concentration-time data. Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-tau) was calculated by the trapezoidal rule (linear up, log down). Area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUC0-inf) was calculated by the trapezoidal rule (Study BPR-PIP-002 only). The fT > MIC of 4 mg/L was calculated using a reported plasma protein-binding estimate of 16%.

The percentage of the dosing interval for which free-drug concentrations remained above an MIC of 4 mg/L (%T > MIC of 4 mg/L) was also calculated using an assumed plasma protein-binding estimate of 16% (Study BPR-PIP-002 only). An MIC of 4 mg/L was selected based on the most conservative European Committee on Antimicrobial Susceptibility Testing cefotaxime nonspecies-specific PK/PD breakpoint (Enterobacteriaceae, 0.25 mg/L; S. aureus, 2 mg/L; S. pneumoniae, 0.5 mg/L; nonspecies-specific PK/PD breakpoint, 4 mg/L).
The following PK parameters were also calculated where possible: the apparent terminal elimination rate constant ($\lambda_z$) was calculated from a semilog plot of the plasma concentration versus time curve by linear least squares regression analysis using the maximum number of points in the terminal log-linear phase using an automated method. The apparent terminal elimination $T_{1/2}$ was calculated as the natural log of 2 divided by $\lambda_z$. Area under the plasma concentration-time curve from time zero to infinity ($AUC_{0\text{-inf}}$) was calculated as $AUC_{0\text{-last}}$ plus the last observed concentration ($C_{\text{last}}$) divided by $\lambda_z$. $AUC_{0\text{-inf}}$ was set to missing if $\lambda_z$ could not be calculated (Study BPR-PIP-001 only). Systemic clearance (CL) was estimated as $\text{Dose} / AUC_{0\text{-inf}}$ (Study BPR-PIP-001 only). Volume of distribution ($V_d$) was estimated as $\text{Dose} / (AUC_{0\text{-inf}} \times \lambda_z)$ (Study BPR-PIP-001 only). Volume of distribution at steady state ($V_{SS}$) was estimated by mean residence time multiplied by CL. The percentage of the administered dose excreted over the urine collection interval ($\text{Ae}$) was calculated as the total amount excreted over the 12-hour period divided by dose and expressed as a percent (Study BPR-PIP-001 only). Clearance at steady state ($CL_{SS}$) was calculated as dose divided by $AUC_{0\text{-tau}}$ (Study BPR-PIP-002 only). The accumulation ratio ($R_{\text{accumulation}}$) was calculated as $1 / (1 - e^{-\lambda_z \times \text{tau}})$. For the open-ring metabolite, the dose-dependent parameters ($CL$, $CL_{SS}$, $V_d$, and $V_{SS}$) were conditioned on the unknown fraction of the dose that is converted to the metabolite.

Summary statistics (number, mean, percent coefficient of variation, median, minimum, and maximum) were tabulated by analyte for the PK parameters.

Data Availability

After publication, the data will be made available to others on reasonable request to Basilea Pharmaceutica International Ltd.
The Pediatric Infectious Disease Journal • Volume 40, Number 11, November 2021

Rubino et al

TABLE 1. Summary Statistics for PK Parameters From the Single-dose Study in Neonates and Infants up to 3 Months of Age (BPR-PIP-001) Derived Using Noncompartmental Methods

| PK Parameter | Ceftobiprole | Ceftobiprole Medocaril | Open-ring Metabolite |
|--------------|--------------|------------------------|----------------------|
| N | Median (Min–Max) | N | Median (Min–Max) | N | Median (Min–Max) |
| C_{max} (μg/mL) | 13 | 11.2 (8.68–32.6) | 13 | 0.107 (0.0149–32.8) | 13 | 0.64 (0.421–1.14) |
| T_{max} (h) | 13 | 4.00 (4.00–4.00) | 13 | 4.00 (2.00–4.00) | 13 | 4.00 (4.00–6.00) |
| AUC_{0–last} (μg•h/mL) | 13 | 60.6 (49.1–126) | 13 | 0.269 (0.0298–66.7) | 13 | 4.80 (3.48–6.76) |
| AUC_{0–inf} (μg•h/mL) | 13 | 66.6 (54.5–130) | – | – | 13 | 5.30 (3.07–18.7) |
| CL (L/h/kg) | 13 | 0.7606 (0.0411–0.995) | – | – | 13 | 0.842 (0.380–1.28) |
| V_{f} (L/kg) | 13 | 0.454 (0.191–0.616) | – | – | 13 | 127 (5.00–10.8) |
| V_{ss} (L/kg) | 13 | 0.480 (0.200–0.670) | – | – | 13 | 8.62 (5.62–12.6) |
| Ae (% of dose) | 13 | 35.9 (0.95–91.4) | 13 | 0.685 (0.25–2.51) | 13 | 3.04 (0.0280–7.26) |
| %fT>MIC of 4 mg/L (h)* | 13 | 5.40 (3.77–8.13) | – | – | – | – |

*Calculated using free-drug concentrations.

As indicates percentage of administered dose excreted in the urine over the collection interval; AUC_{0–last} area under the plasma concentration-time curve from time zero to infinity; AUC_{0–inf} area under the plasma concentration-time curve from time zero to the last measured concentration; CL, oral clearance; C_{max} maximum plasma concentration; CV%, percent coefficient of variation; %fT>MIC, duration of time after dose for which free-drug concentrations remained above the minimum inhibitory concentration; h, hours; L, liters; mg, milligrams; Max, maximum; Min, minimum; mL, milliliters; μg, micrograms; N, number of observations or subjects; PK, pharmacokinetic; T_{max}, half-life; T_{ss}, time at which maximum concentration occurs; V_{f}, volume of distribution; V_{ss}, volume of distribution at steady state.

dose was excreted in the urine as ceftobiprole (~35–40%), open-ring metabolite (~3%), or ceftobiprole medocaril (<1%) over the 12-hour collection interval. Overall, calculated free-ceftobiprole concentrations remained above an MIC of 4 mg/L for a mean of 5.29 hours after the administration of a single dose. This would translate to a mean %fT>MIC of 66% of the dosing interval if the drug was given on an 8-hour schedule and 44% if the drug was given on a 12-hour schedule.

Study BPR-PIP-002

Plasma concentration-time data were available for 29 patients enrolled in Study BPR-PIP-002. Observed PK data stratified by 4 age groups (3 months to 1 year, 2–5 years, 6–11 years, and 12–17 years) for ceftobiprole, ceftobiprole medocaril, and open-ring metabolite are shown in Figure 2. Data from 5 patients were excluded from these figures for the following reasons: 2 patients had contamination of samples due to blood drawn from the infusion line, 2 patients had insufficient sample volume for the majority of samples, and 1 patient had samples provided as whole blood, which were not analyzable. Ceftobiprole peaked at the end of infusion (4 hours for infants and 2 hours for all other age groups). Concentrations of ceftobiprole medocaril and the open-ring metabolite were low overall.

Summary statistics for the ceftobiprole PK parameters, stratified by 4 age groups, are presented in Table 2. The corresponding tables for ceftobiprole medocaril and the open-ring metabolite are available in Tables, Supplemental Digital Content 1, http://links.lww.com/INF/E505, and Supplemental Digital Content 2, http://links.lww.com/INF/E506, respectively, and illustrate that exposure to these 2 analytes was substantially different across age groups, with median values ranging from 1.90 to 2.10 hours. Consistent with the short T_{1/2}, the predicted R_{accumulation} was low for all age groups (1.06–1.08). Calculated free-drug concentrations of ceftobiprole remained above an MIC of 4 mg/L on day 3 for a mean of 5.28 hours when dosed at 10 mg/kg in adolescents 12–17 years of age, 5.74 hours when dosed at 15 mg/kg in children 6–11 years of age, and 6.20 hours when dosed at 20 mg/kg in children 2–5 years of age. These values correspond to mean %fT > MIC values of 73.6%, 76.5%, and 83.7% of the 8-hour dosing interval, respectively. Overall, the %fT>MIC was slightly higher in younger children. The mean %fT>MIC values were 83.7% and 74.8% in children <6 years and those ≥6 years of age, respectively.

Safety

Baseline characteristics of the safety population in each study are presented in Table 3. A total of 15 term neonates (GA ≥37 weeks) were enrolled in Study BPR-PIP-001, all of whom were included in the safety population. Six patients (40%) reported 1 TEAE each. None of these TEAEs were determined to be drug related. Two TEAEs were classified as serious, including 1 (diaphragmatic hernia) that was considered severe. The patient with diaphragmatic hernia, who received ceftobiprole 16 days after birth, had a medical history of a congenital right diaphragmatic hernia repair 2 days after birth. The hernia that occurred during the study period was determined to be a recurrence and not related to the study drug. This serious AE was reported as resolved. The second serious AE was a cerebral infarction that was mild in severity and occurred in a patient with meconium aspiration syndrome. At the last follow-up visit, the event was reported as resolving.

The remaining 4 patients with TEAEs included 2 patients who experienced mild diaper rash, 1 patient who experienced erythema of the hand, and 1 patient who experienced narcotic exposure with withdrawal. No deaths occurred during this study, and no AEs led to treatment discontinuation.
The results of the safety assessment for Study BPR-PIP-002 have been reported previously. Ceftobiprole was generally well tolerated, with most AEs reported as mild or moderate in intensity. The most common AEs reported in this study were diarrhea, headache, and vomiting.

**DISCUSSION**

Plasma and urine concentration-time data collected from full-term neonates and infants enrolled in Study BPR-PIP-001 and pediatric patients 3 months to 17 years of age enrolled in Study BPR-PIP-002 allowed for characterization of the disposition of ceftobiprole. The observed ceftobiprole, ceftobiprole medocaril, and open-ring metabolite plasma concentration-time profiles for patients with pneumonia 3 months to 17 years of age (Study BPR-PIP-002) are presented in Figure 2.

**TABLE 2.** Summary Statistics by Age Group for Ceftobiprole PK Parameters From the Study in Patients With Pneumonia 3 Months to 17 Years of Age (BPR-PIP-002) Derived Using Noncompartmental Methods*

| PK Parameter             | Children (2–5 y) 20 mg/kg IV Over 2 h | Children (6–11 y) 15 mg/kg IV Over 2 h | Adolescents (12–17 y) 10 mg/kg IV Over 2 h |
|--------------------------|--------------------------------------|----------------------------------------|---------------------------------------------|
| N                        | Median (Min–Max)                     | Median (Min–Max)                       | Median (Min–Max)                            |
| Cmax (μg/mL)             | 14 32.4 (20.0–50.8)                  | 6 26.6 (7.44–62.8)                     | 8 17.9 (12.1–27.4)                          |
| Tmax (h)                 | 14 2.03 (2.00–2.17)                  | 6 2.03 (1.80–4.03)                     | 8 2.05 (1.95–2.08)                          |
| AUC0-last (μg•h/mL)      | 14 106 (67.1–167)                    | 6 83.4 (31.8–174)                      | 8 68.1 (40.4–93.6)                          |
| T1/2 (h)                 | 14 2.10 (1.28–5.77)                  | 6 1.90 (1.38–5.17)                     | 8 2.02 (1.43–2.70)                          |
| CLSS (L/h/kg)            | 14 0.147 (0.0930–0.231)              | 6 0.140 (0.0664–0.365)                 | 8 0.113 (0.0618–0.192)                      |
| VSS (L/kg)               | 14 0.462 (0.306–0.725)               | 6 0.460 (0.187–1.28)                   | 8 0.365 (0.226–0.615)                       |
| Raccumulation            | 14 1.08 (1.01–1.62)                  | 6 1.06 (1.02–1.52)                     | 8 1.07 (1.02–1.15)                          |
| %fT>MIC of 4 mg/L (h)‡   | 14 5.98 (3.32–8.01)                  | 6 5.96 (3.58–7.79)                     | 8 5.27 (3.12–7.52)                          |
| %fT>MIC of 4 mg/L2       | 14 77.6 (61.2–100)                   | 6 78.6 (50.8–98.1)                     | 8 71.6 (52.7–96.6)                          |

*There was only one patient in the 3 months to 1 year age group. The PK parameters for this patient are: Cmax, 44.8 μg/mL; AUC0-tau, 174 μg•h/mL; CLSS, 0.800 L/h/kg; VSS, 0.372 L/kg; and %fT>MIC, 7.80 hours.

†Note that AUC0-tau is identical to AUC0-last for all patients as the time of the last observed concentration was within ± 15 minutes of 8 hours in each patient.

‡Calculated using free-drug concentrations.
TABLE 3. Baseline Characteristics in the Safety Populations of the Single-dose Study in Neonates and Infants up to 3 Months of Age (BPR-PIP-001) and the Study in Patients With Pneumonia 3 Months to 17 years of Age (BPR-PIP-002)

| Characteristic | Study BPR-PIP-001 | Study BPR-PIP-002 |
|---------------|------------------|------------------|
| **Sex, n (%)** |                  |                  |
| Male          | 10 (66.7)        | 53 (56.4)        |
| Female        | 5 (33.3)         | 41 (43.6)        |
| **Race, n (%)** |                 |                  |
| White         | 13 (86.7)        | 94 (100)         |
| Black or African American | 1 (6.70) | 0 |
| Native Hawaiian or Other Pacific Islander | 1 (6.70) | 0 |
| **Gestational age (wks)** | Median (range) | Age (y) |
| Median (range) | 39.4 (37.6–41.4) | 5.00 (0.600–17.0) |
| **Postnatal age (d)** | Median (range) |                  |
| Median (range) | 13.0 (5.00–67.0) | 6.00 (1.00–17.0) |
| **Height (cm)** | Median (range) |                  |
| Median (range) | 54.0 (49.0–61.0) | 116 (71.0–184) |
| **Weight (g)** | Median (range) |                  |
| Median (range) | 3980 (2500–5270) | 20.0 (7.00–85.0) |
| **BMI (kg/m²)** | Median (range) |                  |
| Median (range) | 13.8 (10.0–15.6) | 16.2 (8.80–32.8) |

BMI indicates body mass index; cm, centimeters; g, grams; kg, kilograms; m, meters; N, number of observations or subjects.

The Pediatric Infectious Disease Journal • Volume 40, Number 11, November 2021

Rubino et al

The adequacy of expected PK-PD target attainment observed in the subjects that were enrolled in Study BPR-PIP-001 and Study BPR-PIP-002 should not be interpreted as full justification of the dosage regimens used in these 2 studies. First, the dose that was used for the neonates and infants enrolled in Study BPR-PIP-001 was selected specifically for the primary objective of that study (ie, to evaluate PK). To that end, a single dose of 7.5 mg/kg administered over 4 hours was used to ensure that the particularly vulnerable subjects enrolled in the study were not subjected to unnecessarily high cephalobiprole exposures given that there was no therapeutic intent for cephalobiprole. On the other hand, the doses used in Study BPR-PIP-002 were selected based on the fact that it was an efficacy study. Thus, higher doses were selected to ensure that subjects achieved cephalobiprole exposures that were associated with efficacy in adult phase 3 studies. While the doses used in Study BPR-PIP-002 were appropriate based on the clinical efficacy results of the study, less complex dosing regimens with consistent infusion durations across age categories could theoretically provide similarly appropriate cephalobiprole exposures. A thorough examination of such alternative dosing regimens is outside the scope of this analysis.

Rational use of antibiotics in pediatric patients requires a thorough examination of not only the safety and efficacy but also the PK in this population. The results of the PK analyses provide important information in that regard. However, the use of noncompartamental methods for evaluating the PK has limitations in terms of the precision of the resultant PK parameter estimates (due to the

cfobiprole, cephalobiprole medocaril, and the open-ring metabolite in this population. Like in adults,2 the prodrug (ceftobiprole medocaril) is rapidly converted to active ceftobiprole in the pediatric population with peak concentrations of ceftobiprole observed immediately after the end of the infusion. Exposure to cephalobiprole in plasma was demonstrated to be substantially higher than that for cephalobiprole medocaril and the open-ring metabolite. Consistent with this observation, the majority of drug recovered in urine from subjects enrolled in Study BPR-PIP-001 was in the form of ceftobiprole. As observed in adults (mean ± SD T 1/2 of 3.3 ± 0.3 hours),4 the T 1/2 of ceftobiprole was short in the pediatric population with median values ranging from 1.90 hours in children 6–11 years of age to 2.86 hours in full-term neonates. The longer T 1/2 in neonates is likely secondary to immature renal function in this cohort.22 Overall exposure to cephalobiprole in the pediatric patients (median AUC ranging from 66.6 to 173 μg•h/mL) was also similar to that observed in healthy adults receiving 500 mg q8h (mean ± SD of 102 ± 11.9 μg•h/mL).2 The pediatric patients enrolled in Study BPR-PIP-002 exhibited faster CL SS and larger V SS than healthy, adult volunteers. The median CL SS estimates ranged from 0.113 to 0.147 L/h/kg in pediatric patients 2 years of age or older in Study BPR-PIP-002 compared with 0.072 L/h/kg for adults enrolled in a phase 1, multiple-dose study (assuming a mean body weight of 70 kg).3 The median V SS ranged from 0.365 to 0.462 L/kg in pediatric patients 2 years of age or older in Study BPR-PIP-002 compared with 0.239 L/kg for adults enrolled in the same phase 1, multiple-dose study.4

To assess the adequacy of drug concentrations in pediatric patients in terms of likely clinical efficacy, the FT > MIC for a nominal MIC value of 4 mg/L was evaluated using the observed ceftobiprole concentrations. This PK-PD index was chosen as the time that free-drug concentrations remain above the MIC of an infecting organism has been identified as the PK-PD driver for β-lactam antibiotics, including ceftobiprole.13,14 The hypothetical MIC of 4 mg/L was considered a conservative target MIC given that it is the highest MICc value for cephalobiprole across relevant bacterial species.21 The lowest observed %FT>MIC was 50.8%, which suggests that overall PK-PD target attainment can be expected to be sufficient in pediatric patients. Protein binding of cephalobiprole in this pediatric population was kept identical to the protein-binding estimate for the adult population (16%).12 This was based on a relatively low protein binding of cephalobiprole in adults that is independent of drug concentration and the lack of available neonatal and pediatric data. For some other antibiotics, higher unbound drug fractions in neonates or children are observed compared with adults.24–26 Therefore, the lack of measured free-drug concentrations is a limitation of this analysis and the %FT>MIC estimates from this analysis should be interpreted with caution.
relative sparseness of the PK sampling schemes) and the quantification of the variability in ceftobiprole PK in children and factors that drive that variability. Use of population PK modeling techniques have the potential to address these issues. To that end, future analyses utilizing modeling and simulation approaches to more fully explore ceftobiprole dosing regimens that are most likely to be safe and effective in children are warranted.

ACKNOWLEDGMENTS

The authors would like to thank the investigators, site staff, patients, and their parents/legal guardians.

REFERENCES

1. Lupia T, Corcione S, Mornese Pinna S, et al. New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis. 2020;12:3747–3763.
2. Flamm RK, Duncan LR, Hamed KA, et al. Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. Antimicrob Agents Chemother. 2020;64:e02566–e02519.
3. Giacobbe DR, De Rosa FG, Del Bon V, et al. Ceftobiprole: drug evaluation and place in therapy. Expert Rev Anti Infect Ther. 2019;17:689–698.
4. Electronic Medicines Compendium. Zetavera 500mg powder for concentrate for solution for infusion. 2019. Available at: https://www.medicines.org.uk/emc/product/9164. Accessed February 23, 2021.
5. Overcash J, Kim C, Keech R, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET) [published online ahead of print September 8, 2020]. Clin Infect Dis. doi: 10.1093/cid/ciaa974.
6. Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol. 2020;15:35–48.
7. Grau S. Safety and tolerability of ceftobiprole. Rev Esp Quimioter. 2019;32(suppl 3):34–36.
8. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48:2576–2580.
9. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48:2570–2575.
10. Kimko H, Murthy B, Xu X, et al. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009;53:1228–1230.
11. Muller AE, Schmitt-Hoffmann AH, Punt N, et al. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in monomicrobial pneumonia patients: a validation study. Antimicrob Agents Chemother. 2013;57:2047–2053.
12. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47:21–33.
13. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52:3492–3496.
14. Rubino CM, Bradley JS. Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics. Paediatr Drugs. 2007;9:361–369.
15. Le J, Bradley JS. Optimizing antibiotic drug therapy in pediatrics: current state and future needs. J Clin Pharmacol. 2018;58(suppl 10):S108–S122.
16. Blumer JL, Schmitt-Hoffman A, Engelhardt M, et al. Pharmacokinetics of ceftobiprole in paediatric patients [abstract 1252]. In: 26th Annual European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9 to 12, 2016.
17. Bosheva M, Gujnadze R, Károly É, et al. A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatr Infect Dis J. 2021;40:e222–e229.
18. ClinicalTrials.gov [Internet]. Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics. Bethesda, MD: National Library of Medicine (US). Identifier NCT02527681, July 7, 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02527681. Accessed February 23, 2021.
19. ClinicalTrials.gov [Internet]. Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia. Bethesda, MD: National Library of Medicine (US). Identifier NCT03439124. October 8, 2020. Available at: https://clinicaltrials.gov/ct2/show/results/NCT03439124. Accessed February 23, 2021.
20. R [computer program]. Version 3.6.1. Vienna, Austria: R Development Core Team; R Foundation for Statistical Computing; 2019.
21. European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, January 2019. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf. Accessed February 23, 2021.
22. De Cock RF, Allegaert K, Brussee JM, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31:2643–2654.
23. Pfluger MA, Flamm RK, Mendes RE, et al. Ceftobiprole activity against gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2019;63:e01566–e01518.
24. Sando M, Sato Y, Iwata S, et al. In vitro protein binding of teicoplanin to neonatal serum. J Infect Chemother. 2004;10:280–283.
25. Pullen J, Stolk LM, Degraeuwe PL, et al. Protein binding of fluocxacillin in neonates. Ther Drug Monit. 2007;29:279–283.
26. Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37:1503–1510.